Key result
Eptifibatide infusion in STEMI linked to severe thrombocytopenia of 3000/µL and gross hematuria.
Why the study?
Eptifibatide can rarely be associated with severe thrombocytopenia, creating a management dilemma in patients requiring antiplatelet therapy.
Case Report (n=1)
No
Eptifibatide infusion can rarely cause profound, rapid-onset thrombocytopenia and bleeding, requiring prompt cessation of the drug and potentially platelet transfusion.
Eptifibatide is a platelet glycoprotein (GP) IIb/IIIa inhibitor that is used in certain cases of acute coronary syndrome, including those with high thrombus burden or with no-reflow. It can rarely be associated with severe thrombocytopenia, which brings up a dilemma in managing those patients who require antiplatelet therapy. We discuss a patient who had ST-elevation myocardial infarction (STEMI) and developed severe thrombocytopenia after eptifibatide infusion. He was managed with platelet transfusion, stopping eptifibatide, and interrupting dual antiplatelet therapy (DAPT).
No takes yet. Share an insight, caveat, or question.
Gheith et al. (2022) conducted a case report in ST-elevation myocardial infarction (STEMI) (n=1). Eptifibatide was evaluated. Eptifibatide infusion in a 69-year-old man with STEMI resulted in severe thrombocytopenia with a platelet count of 3000/µL and gross hematuria within 12 hours, resolving after discontinuation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: